Researcher Profile

Researcher Profile

Lisa McGregor, MD, PhD

Lisa McGregor, MD, PhD

Howard O. Jr. and Jean S. Beaver Professor of Pediatric Hematology/Oncology, Department of Pediatrics
Chief, Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Pediatric Cancer
lmm56@psu.edu

Research Interests

  • Neoplasms
  • Child
  • Neuroblastoma
  • Pediatrics
  • Irinotecan
  • Radiotherapy
  • Gefitinib
  • Survival
  • Pharmacokinetics
  • Oxaliplatin
  • Wilms Tumor
  • Young Adult

Clinical Trials

Umbrella Long-term Follow-up Protocol
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Neuroblastoma Biology Studies
Renal Tumor Classification, Biology, and Banking Study
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed or Refractory Solid Tumors or Hematologic Malignancies
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib (IbranceĀ®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
AGCT1532, Randomized Phase 3 Trial of Accelerated vs Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastic Germ Cell Tumors
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Asparaginase
A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by Maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Recent Publications

2020

Santana, VM, Sahr, N, Tatevossian, RG, Jia, S, Campagne, O, Sykes, A, Stewart, CF, Furman, WL & McGregor, LM 2020, 'A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors', Cancer, vol. 126, no. 8, pp. 1749-1757. https://doi.org/10.1002/cncr.32722
Rao, P, Segel, JE, McGregor, LM, Lengerich, EJ, Drabick, JJ & Miller, B 2020, 'Attendance at National Cancer Institute and Children's Oncology Group Facilities for Children, Adolescents, and Young Adults with Cancer in Pennsylvania: A Population-Based Study', Journal of Adolescent and Young Adult Oncology, vol. 9, no. 1, pp. 47-54. https://doi.org/10.1089/jayao.2019.0045

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)